Michael Goldberg, a director at CareDx, Inc., has reported the sale of 10,800 shares of the company’s common stock. This action occurred under a Rule 10b5-1 trading plan and was executed on November 12, 2026. The sales are significant as they reflect the ongoing management decisions within the medical laboratory services sector.

Background

CareDx, Inc. is a company focused on providing medical laboratory services, particularly in the field of transplant diagnostics. The company is incorporated in Delaware and has its headquarters in Brisbane, California. CareDx trades under the ticker symbol CDNA and is classified under the SIC code for medical laboratories.

What the Filing Says

According to the recent filing, Goldberg sold shares at various prices, with a total of 10,800 shares disposed of. The transactions were reported as follows:

“The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.74 to $78.72 per share.”

Goldberg's ownership following these transactions stands at 48,526 shares.

Impact

This series of transactions may influence investor perceptions of CareDx and its management’s confidence in the company’s future. As a director, Goldberg's actions could be closely monitored by shareholders and industry analysts alike.

What's Next

The filing does not say what happens next.